Loxo oncology, inc. (LOXO)
Income statement / TTM
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue from collaboration agreement

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development with related party

-

-

-

-

-

-

-

-

-

-

-

11,611

9,874

9,413

8,211

7,568

13,554

0

0

0

Research and development

161,191

169,017

151,860

140,039

132,679

82,155

70,088

58,275

40,778

29,935

20,397

13,956

10,547

9,868

8,095

6,947

4,532

0

0

0

General and administrative

56,489

50,305

41,078

33,657

25,012

19,011

16,282

14,903

14,036

12,909

11,510

10,508

9,856

8,926

7,707

6,175

3,809

0

0

0

Total operating expenses

217,680

219,322

192,938

173,696

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-72,880

-116,992

-133,209

-152,396

-157,691

-101,166

-86,370

-73,178

-58,714

-49,618

-41,600

-36,075

-30,277

-28,207

-24,013

-20,690

0

0

0

-

Interest income, net

9,904

7,761

5,303

3,520

2,249

1,352

1,041

780

643

467

309

199

0

0

0

-

-

-

-

-

Net loss

-62,976

-109,231

-127,906

-148,876

-155,442

-99,814

-85,329

-72,398

-58,071

-49,151

-41,291

-35,876

-30,131

-28,103

-23,952

-20,672

-21,895

0

0

0

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34

0

0

0

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20,706

-21,929

0

0

0

Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)

-0.89

-0.39

-0.12

-0.76

-2.45

-1.14

-0.96

-1.28

-0.82

-0.77

-0.59

-0.72

-0.53

-0.49

-0.38

26.30

-0.68

-14.46

-14.22

-45.20

Weighted average shares outstanding, basic and diluted diluted (in shares)

30,502

30,156

30,025

30,015

29,872

26,586

25,668

21,879

21,609

20,587

19,544

18,002

16,560

16,540

16,474

16,671

9,947

271

204

184